Fri, November 19, 2021

David Lebowitz Maintained (ARQT) at Buy with Decreased Target to $35 on, Nov 19th, 2021

David Lebowitz of Morgan Stanley, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Buy with Decreased Target from $50 to $35 on, Nov 19th, 2021.

David, nor any peers, have made any analyst calls on ARQT in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30